Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment Algorithm

Prospective Clinical Study to Evaluate the Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment Algorithm

This is a prospective, comparative, randomized, controlled, open-label, single-surgeon, single-center PMCF clinical study whereby presbyopic patients undergoing refractive surgery will receive a SUPRACOR treatment for the correction in the non-dominant eye and a PROSCAN refractive treatment in the dominant eye to correct for ametropia.

The participants will be randomized to either a SUPRACOR regular (100%) or SUPRACOR strong (130%) treatment with a 1:1 ratio.

Inclusion Criteria:

• presbyopia
• willingness for a refractive presbyopia correction
• signed informed consent form

Exclusion Criteria:

- ocular comorbidity